Stock 4571 NANO MRNA CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News NANO MRNA Co.,Ltd.

Equities

4571

JP3651120002

Delayed Japan Exchange
Other stock markets
 12:39:42 2024-05-09 am EDT 		5-day change 1st Jan Change
181 JPY +0.56% Intraday chart for NANO MRNA Co.,Ltd. +1.12% -4.74%
2023 NANO MRNA, Kao Tie Up to Develop mRNA Therapies for Allergic Diseases MT
2023 NANO MRNA Co., Ltd. and Kao Corporation Agree a Comprehensive Collaborative Research for mRNA Drug Discovery CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NANO MRNA, Kao Tie Up to Develop mRNA Therapies for Allergic Diseases
MT
NANO MRNA Co., Ltd. and Kao Corporation Agree a Comprehensive Collaborative Research for mRNA Drug Discovery
CI
NanoCarrier Co., Ltd. announced that it has received ¥13.6793 million in funding from Axcelead Inc., IPGaia, Inc.
CI
NanoCarrier Co., Ltd. announced that it expects to receive ¥13.6793 million in funding from Axcelead Inc., IPGaia, Inc.
CI
NanoCarrier Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023
CI
US Patent Office Grants Patrys Two New Deoxymab Patents
MT
NanoCarrier Co., Ltd. announced that it has received ¥1.11096909 billion in funding from Whiz Partners Inc.
CI
NanoCarrier Co., Ltd. announced that it expects to receive ¥1.11096909 billion in funding from Whiz Partners Inc.
CI
NanoCarrier Co., Ltd. Reports Earnings Results for the Half Year Ended September 30, 2022
CI
NanoCarrier : Commences in Domestic Patients Administration of VB-111, a gene therapy product Global Phase III Trial in Platinum-Resistant Ovarian Cancer
PU
NanoCarrier Co., Ltd. Commences in Domestic Patients Administration of VB-111, A Gene Therapy Product Global Phase III Trial in Platinum-Resistant Ovarian Cancer
CI
NanoCarrier Co., Ltd. announced that it expects to receive ¥1.15292206 billion in funding from THE KENKO FUTURE Limited Partnership
CI
Nanocarrier : Concludes NC-6004 Phase III Clinical Study for Pancreatic Cancer
MT
NanoCarrier Announces the Conclusion of NC-6004 Phase III Clinical Study for Pancreatic Cancer
CI
Nanocarrier : Administers Head and Neck Cancer Drug NC-6004 to First Patient
MT
Nanocarrier Co., Ltd. Starts Administering NC-6004 in the Phase IIb Clinical Study in Combination with Keytruda for Head and Neck Cancer
CI
NanoCarrier Presents Favorable Data from Phase IIa Portion of NC-6004 Phase II Clinical Study in Combination with Keytruda
CI
NanoCarrier Co., Ltd. completed the acquisition remaining 92.62% AccuRna, Inc. from Fast Track Initiative No. 2 Investment Business Limited Liability, SMBC Venture Capital Co., Ltd., Innovation Platform Development No. 1 Fund, fund managed by UTokyo Innovation Platform Co., Ltd. and Kazunori Kataoka.
CI
NanoCarrier Co., Ltd. Announces the First Participant Dosed in Investigator-Initiated Phase I Clinical Trial in Patients with Breast Cancer in Japan
CI
NanoCarrier Co., Ltd. signed an agreement to acquire remaining 92.62% AccuRna, Inc. from Fast Track Initiative No. 2 Investment Business Limited Liability, SMBC Venture Capital Co., Ltd., Innovation Platform Development No. 1 Fund, fund managed by UTokyo Innovation Platform Co., Ltd. and Kazunori Kataoka for ¥1.7 billion.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4571 Stock
  4. News NANO MRNA Co.,Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW